Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
Kristian B FilionAntonios DourosLaurent AzoulayHui YinOriana H YuSamy SuissaPublished in: British journal of clinical pharmacology (2019)
Initiating treatment of type 2 diabetes with a sulfonylurea rather than metformin is associated with higher rates of ischaemic stroke, cardiovascular death, and all-cause mortality.